 Bausch Health has seen a very tough 2022 as investors price in higher interest rates on its massive debt load and softer IPO of its subsidiary Bausch Lomb. These are not encouraging trends, but the valuation reset has been enormous, potentially creating an opportunistic investment opportunity here. 